Orient Bio

Orient Bio Net Change in Cash

The Net Change in Cash of Orient Bio (002630.KS) as of Nov 3, 2026 is -699.57 M KRW. In the previous year, Net Change in Cash was 422.91 M KRW — a change of -265.42% (lower).

Net Change in Cash

-699.57 MKRW

YoY

-265.42%

Last updated:

Net Change in Cash of Orient Bio is 2026 -699.57 M KRW. Net Change in Cash of Orient Bio was 2025 422.91 M KRW. It decreases by -265.42% lower compared to the previous year.

The Orient Bio Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2019
-15.27 B KRW
Jan 1, 2020
-6.82 B KRW
Jan 1, 2021
8.59 B KRW
Jan 1, 2022
19.05 B KRW
Jan 1, 2023
-24.06 B KRW
Jan 1, 2024
174.72 M KRW
Jan 1, 2025
422.91 M KRW
Jan 1, 2026
-699.57 M KRW
The Orient Bio Net Change in Cash history
YEARNet Change in CashYoY
-699.57 MKRW-265.42%
422.91 MKRW+142.06%
174.72 MKRW-100.73%
-24.06 BKRW-226.27%
19.05 BKRW+121.79%
8.59 BKRW-225.95%
-6.82 BKRW-55.33%
-15.27 BKRW-381.27%
5.43 BKRW-48.65%
10.57 BKRW+47.02%
7.19 BKRW+5,871.41%
120.41 MKRW-114.58%
-825.72 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Net Change in Cash of Orient Bio is -699.57 M KRW in 2026.

Net Change in Cash of Orient Bio changed from 422.91 M KRW to -699.57 M KRW, representing a -265.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Orient Bio

All Key Metrics — Orient Bio